Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
Bioarctic Disease Development Equipment Supplied In Europe
7 equipment items found
Manufactured by:BioArctic AB based inStockholm, SWEDEN
The antibody PD1601 is targeting alpha-synuclein for treatment of Parkinson’s disease. The aim is to develop a disease modifying treatment that stops or slows down disease progression. The project is conducted in collaboration with ...
Manufactured by:BioArctic AB based inStockholm, SWEDEN
The antibody PD1602 is targeting alpha-synuclein for treatment of Parkinson’s disease. The aim is to develop a disease modifying treatment that stops or slows down disease progression. The project is conducted in collaboration with ...
Manufactured by:BioArctic AB based inStockholm, SWEDEN
AD1503 is an innovative project to develop a disease modifying treatment for prodromal and mild Alzheimer’s disease. ...
Manufactured by:BioArctic AB based inStockholm, SWEDEN
AD1502 is an innovative project to develop a disease modifying treatment for prodromal and mild Alzheimer’s disease. ...
Manufactured by:BioArctic AB based inStockholm, SWEDEN
The drug candidate ABBV-0805 is a monoclonal antibody that selectively binds and eliminates oligomers and protofibrils of alpha-synuclein. The goal is to develop a disease modifying treatment that stops or slows down disease ...
Manufactured by:BioArctic AB based inStockholm, SWEDEN
AD1801 is an innovative project to develop disease modifying treatment of Alzheimer’s disease, targeting Apolipoprotein E (ApoE), a different molecule than those targeted in the projects BAN2401 and BAN2401 ...
Manufactured by:BioArctic AB based inStockholm, SWEDEN
Research to develop new antibodies for treating neurodegenerative disorders is under way at BioArctic. the ND3014 project aims to develop selective antibody treatments targeting TDP-43, a protein that is believed to play a crucial role in the development of the rare neurodegenerative disease ALS (amyotrophic lateral ...